Lv Xiaolei, Gu Ming, Wang Junfeng, Xu Haojun, Li Xiangquan, Chen Yafang
Altern Ther Health Med. 2023 Oct;29(7):382-387.
This study aims to investigate the effectiveness of levosimendan in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection complicated by cardiac insufficiency and myocardial injury.
A total of 22 patients with SARS-CoV-2 infection and myocardial injury, admitted to the Cardiology Department of our hospital between December 2022 and February 2023, are randomly divided into two groups: a dobutamine general treatment group and a levosimendan observation treatment group. The treatment outcomes of the two groups are compared and analyzed.
The overall improvement rate in the general treatment group is 80%, while the levosimendan treatment group shows a 100% improvement rate. There is a statistically significant difference between the two groups (P < .05). Post-treatment, the left ventricular ejection fraction for the general treatment group and the levosimendan treatment group are (48 ± 7)% and (54 ± 6)%, respectively. Additionally, the left ventricular end-diastolic diameter is (55.0 ± 3.0) mm in the general treatment group and (51 ± 5.0) mm in the levosimendan group, with a statistically significant difference (P < .05). After active treatment, the plasma levels of B-type natriuretic peptide (Brain Natriuretic Peptide, NT-proBNP) are significantly lower in the levosimendan treatment group than in the general treatment group (P < .05). Moreover, the plasma levels of interleukin-6 (IL-6) and C-reactive protein (CRP) in the levosimendan group decrease slightly faster than those in the general treatment group, with a statistically significant difference (P < .05). The length of hospital stay in the levosimendan group is (12 ± 3) days, significantly lower than the general treatment group (16 ± 5) days, with a statistically different result (P < .05).
Levosimendan demonstrates significant efficacy in patients with novel coronavirus infection complicated by myocardial injury, resulting in improved clinical symptoms, enhanced cardiac function, shorter hospital stays, early discharge, and cost savings.
本研究旨在探讨左西孟旦对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染合并心功能不全及心肌损伤患者的疗效。
选取2022年12月至2023年2月期间我院心内科收治的22例SARS-CoV-2感染合并心肌损伤患者，随机分为两组：多巴酚丁胺常规治疗组和左西孟旦观察治疗组。比较分析两组的治疗效果。
常规治疗组的总体改善率为80%，而左西孟旦治疗组的改善率为100%。两组间差异有统计学意义（P <.05）。治疗后，常规治疗组和左西孟旦治疗组的左心室射血分数分别为（48±7）%和（54±6）%。此外，常规治疗组的左心室舒张末期内径为（55.0±3.0）mm，左西孟旦组为（51±5.0）mm，差异有统计学意义（P <.05）。积极治疗后，左西孟旦治疗组的血浆B型利钠肽（脑钠肽，NT-proBNP）水平显著低于常规治疗组（P <.05）。此外，左西孟旦组的白细胞介素-6（IL-6）和C反应蛋白（CRP）血浆水平下降速度略快于常规治疗组，差异有统计学意义（P <.05）。左西孟旦组的住院时间为（12±3）天，显著低于常规治疗组（16±5）天，差异有统计学意义（P <.05）。
左西孟旦对新型冠状病毒感染合并心肌损伤患者显示出显著疗效，可改善临床症状，增强心功能，缩短住院时间，实现早期出院并节省费用。
